Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Ozkurt, Zübeyde Nur  [Clear All Filters]
2014
Acar K, Akı SZeynep, Ozkurt ZNur, Bozdayı G, Rota S, Sucak GTürköz. Factors Associated with Cytomegalovirus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation: Human Leukocyte Antigens Might Be Among the Risk Factors. Turk J Haematol. 2014;31(3):276-285.
2023
Değirmenci BBostankolu, Yegin ZArzu, Akdemir ÜÖzgür, Dede A, Gündem GGül, Ozkurt ZNur, Atay LÖzlem, Yağci M. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care. Ann Hematol. 2023.
Penack O, Peczynski C, Boreland W, Lemaitre J, Afanasyeva K, Kornblit B, Jurado M, Martínez C, Natale A, Pérez-Simón JAntonio, et al. ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party. Front Immunol. 2023;14:1283034.
Yegin ZArzu, Savaş EMerve, Yildiz S, Kök Mİrem, Erdemir MBüşra, Değirmenci BBostankolu, Ozkurt ZNur, Yağci M. Preconditioning Modified-Easix as a Predictor of Prognosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Indian J Hematol Blood Transfus. 2023;39(4):586-597.
Waszczuk-Gajda A, Gras L, de Wreede LC, Sirait T, Illés Á, Ozkurt ZNur, Snowden JA, Arat M, Bulabois CEric, Niederland J, et al. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2023.
2024
Savaş EMerve, Yegin ZArzu, Kök Mİrem, Karayel HTuğba, Ozkurt ZNur, Bozer MNazlı, Çamoğlu M, Gülbahar Ö. Hypomagnesemia May Predict Better Survival and Reduced Nonrelapse Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Transplant Proc. 2024.
Beksac M, Eikema D-J, Koster L, Hulin C, Poire X, Hamladji R-M, Gromek T, Bazarbachi A, Ozkurt ZNur, Pabst T, et al. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024.